Molecular Trading And Mercantile Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 1.00 M
as on 23-10-2024
- Company Age 25 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 36.05%
(FY 2023)
- Profit 92.75%
(FY 2023)
- Ebitda 40.72%
(FY 2023)
- Net Worth 60.77%
(FY 2023)
- Total Assets 1.52%
(FY 2023)
About Molecular Trading And Mercantile
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Kisanchand and Mohan Karanje serve as directors at the Company.
- CIN/LLPIN
U51900MH1999PTC120186
- Company No.
120186
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Molecular Trading And Mercantile?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Kisanchand  | Director | 18-Mar-2024 | Current |
| Mohan Karanje | Director | 13-May-2020 | Current |
Financial Performance and Corporate Structure Insights of Molecular Trading And Mercantile.
Molecular Trading And Mercantile Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.05% increase. The company also saw a substantial improvement in profitability, with a 92.75% increase in profit. The company's net worth Soared by an impressive increase of 60.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Molecular Trading And Mercantile?
In 2023, Molecular Trading And Mercantile had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sarnam Trading And Mercantile Private LimitedActive 21 years 6 monthsAtul Kisanchand and Mohan Karanje are mutual person
- Strategic Capital Corporation Private LimitedActive 32 years 9 months
Atul Kisanchand is a mutual person
- Saturn Advisory Services Private LimitedActive 19 years 10 months
Atul Kisanchand is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Molecular Trading And Mercantile?
Unlock and access historical data on people associated with Molecular Trading And Mercantile, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Molecular Trading And Mercantile, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Molecular Trading And Mercantile's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
